Clinical Trial Update: Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Endostar in combination with toripalimab as adjuvant therapy for resectable stage III or oligometastatic stage IV cutaneous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Endostar (recombinant human endostatin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Fudan University | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Status: UNKNOWN